GSK Reaches ‘First Base’ In Hep B Functional Cure But Has More To Prove

9% Disease Free After Phase II Study

GSK is the first to raise the functional cure rate with its antisense drug, Phase II data suggest, but the company is looking for ways to boost responses across hepatitis B patients in its Phase III study.

Hepatitis B virus
Hepatitis B has so far proven very difficult to suppress - but GSK is hoping to achieve a functional cure for more patients in its Phase III study • Source: Shutterstock

Recent weeks have seen a flurry of Phase III trial readouts from GSK, ranging from a definite ‘win’ (for its RSV vaccine) to a clear failure (with myeloma therapy Blenrep) in the company’s efforts to bring a new generation of blockbusters to market. The firm has now added to this with Phase II results showing a small number of patients have achieved a functional cure when treated with its chronic hepatitis B (CHB) candidate bepirovirsen. (Also see "GSK’s Blenrep Hit By Trial Failure, Raising Questions About Its Future In The Myeloma Market" - Scrip, 7 November, 2022.) 

The data might not be a clear win just yet, but do set up GSK to move in to Phase...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Clinical Trials

  • Sciwind Eyes Differentiation For Ecnoglutide In Highly Competitive Arena

     
    • By 

    Chinese firm Sciwind has revealed additional Phase III findings for its promising once-weekly GLP-1 agonist ecnoglutide, just one asset in a burgeoning Chinese sector that could see the emergence of new rivals to current global leaders in obesity and diabetes.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

     
    • By 

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

  • Sponsored By:

    Nancy Tests SPARC-931-part

    The article discusses the impact of upcoming patent expirations in oncology biologics on biosimilar developers, highlighting the opportunities in Antibody-Drug Conjugates (ADCs) and Bispecific Antibodies (BsAbs). It explores the challenges posed by the structural complexities of these biologics, necessitating new bioanalytical tools and manufacturing processes. The evolving regulatory landscape, with contributions from EMA, FDA, and WHO, offers flexible pathways but also presents challenges. The article underscores the potential for biosimilars to generate significant cost savings and enhance patient access to cancer treatments over the next decade.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

More from R&D